The Effects of Agave Fructans in a Functional Food Consumed by Patients with Irritable Bowel Syndrome with Constipation: A Randomized, Double-Blind, Placebo-Controlled Trial

被引:5
作者
Camacho-Diaz, Brenda Hildeliza [1 ]
Arenas-Ocampo, Martha Lucia [1 ]
Osorio-Diaz, Perla [1 ]
Jimenez-Aparicio, Antonio Ruperto [1 ]
Alvarado-Jasso, Guadalupe Monserrat [2 ]
Saavedra-Briones, Eden Valfre [3 ]
Valdovinos-Diaz, Miguel angel [4 ]
Gomez-Reyes, Elisa [5 ]
机构
[1] Inst Politecn Nacl, Ctr Desarrollo Prod Biot, Yautepec 62731, Morelos, Mexico
[2] Ctr Nacl Tecnol & Seguridad Alimentaria CNTA, Ctra NA-134 Km 53, San Adrian 31570, Navarra, Spain
[3] Univ Autonoma Estado Morelos, Fac Nutr, Cuernavaca 62290, Morelos, Mexico
[4] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Gastrointestinal Motilidad Lab, Dept Gastroenterol, Ciudad De Mexico 14080, Mexico
[5] Tecnol Monterrey, Escuela Med & Ciencias Salud, Campus Ciudad Mexico,Calle Puente 222, Ciudad De Mexico 14380, Mexico
关键词
IBS; constipation; prebiotic jelly; agave fructans; functional foods; prebiotics; fiber intake; intestinal movements; QUALITY-OF-LIFE; MEXICAN CONSENSUS; GUT MICROBIOTA; DIETARY FIBER; DEPRESSION; IBS; VALIDATION; ANXIETY; ALTERS;
D O I
10.3390/nu15163526
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Irritable bowel syndrome displays three different subtypes: constipation (IBS-C), diarrhea (IBS-D), and mixed (IBS-M). Treatment with dietary fiber is used, with consideration given both to the chemical composition of the fiber and to the different subtypes of IBS. The IBS-D subtype is usually treated with a low-FODMAPs diet, whereas the IBS-C subtype suggests prebiotics and probiotics to promote microbiota restoration. The aim of this study was to assess the effects of employing agave fructans as the soluble fiber of a jelly (Gelyfun (R) gastro) containing 8 g per serving in the IBS-C group (n = 50), using a randomized, double-blind, time-limited trial for four weeks. We evaluated changes in the frequency and types of bowel movements through the Bristol scale, and the improvement of the condition was evaluated using quality of life (IBS-QOL) and anxiety-depression (HADS) scales. The main results were that the number of bowel movements increased by more than 80%, with at least one stool per day from fifteen days onwards, without a laxative effect for the group treated. Finally, the quality of life with the prebiotic jelly was significantly improved compared to the placebo in all specific domains, in addition to significantly reducing anxiety and depression.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Effects of kivia powder on Gut health in patients with occasional constipation: a randomized, double-blind, placebo-controlled study
    Udani, Jay K.
    Bloom, David W.
    NUTRITION JOURNAL, 2013, 12
  • [42] Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial
    Lacy, Brian E.
    King, Jennifer
    Shortino, Denise
    Schaumburg, Chris
    Haag-Molkenteller, Cornelia
    Chey, William D.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2022, 34 (12)
  • [43] Randomized, Double-Blind, Placebo-Controlled Parallel Clinical Trial Assessing the Effect of Fructooligosaccharides in Infants with Constipation
    Souza, Daniela da Silva
    Tahan, Soraia
    Weber, Thabata Koester
    de Araujo-Filho, Humberto Bezerra
    de Morais, Mauro Batista
    NUTRIENTS, 2018, 10 (11)
  • [44] Non-Celiac Gluten Sensitivity Has Narrowed the Spectrum of Irritable Bowel Syndrome: A Double-Blind Randomized Placebo-Controlled Trial
    Shahbazkhani, Bijan
    Sadeghi, Amirsaeid
    Malekzadeh, Reza
    Khatavi, Fatima
    Etemadi, Mehrnoosh
    Kalantri, Ebrahim
    Rostami-Nejad, Mohammad
    Rostami, Kamran
    NUTRIENTS, 2015, 7 (06): : 4542 - 4554
  • [45] Effectiveness of a Balanced Nine-Strain Synbiotic in Primary-Care Irritable Bowel Syndrome Patients-A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial
    Sommermeyer, Henning
    Chmielowiec, Krzysztof
    Bernatek, Malgorzata
    Olszewski, Pawel
    Kopczynski, Jaroslaw
    Piatek, Jacek
    NUTRIENTS, 2024, 16 (10)
  • [46] The Effect of Lactobacillus reuteri Supplementation in Adults with Chronic Functional Constipation: a Randomized, Double-Blind, Placebo-Controlled Trial
    Ojetti, Veronica
    Ianiro, Gianluca
    Tortora, Annalisa
    D'Angelo, Giovanna
    Di Rienzo, Teresa Antonella
    Bibbo, Stefano
    Migneco, Alessio
    Gasbarrini, Antonio
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2014, 23 (04) : 387 - 391
  • [47] Effect of Portulaca Oleracea L. extract on functional constipation: A randomized, double-blind, placebo-controlled trial
    Bang, Ki Bae
    Choi, Jung Ho
    Park, Jee Hun
    Lee, Seong
    Rho, Mun-Chual
    Lee, Seung W.
    Lee, Soyoung
    Shin, Jeong Eun
    SAUDI JOURNAL OF GASTROENTEROLOGY, 2022, 28 (04) : 296 - +
  • [48] Effect of Korean Herbal Medicine Combined with a Probiotic Mixture on Diarrhea-Dominant Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo-Controlled Trial
    Ko, Seok-Jae
    Han, Gajin
    Kim, Seul-Ki
    Seo, Jae-Gu
    Chung, Won-Seok
    Ryu, Bongha
    Kim, Jinsung
    Yeo, Inkwon
    Lee, Beom-Joon
    Lee, Jin-Moo
    Park, Jae-Woo
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2013, 2013
  • [49] Efficacy of a Synbiotic Containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in Elderly Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
    Oh, Joo Hyun
    Jang, Yeon Sil
    Kang, Danbee
    Kim, Hong Seog
    Kim, Eui-Joong
    Park, So-Young
    Kim, Cheol-Hyun
    Min, Yang Won
    Chang, Dong Kyung
    GUT AND LIVER, 2023, 17 (01) : 100 - 107
  • [50] The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial
    Bai, Tao
    Zeng, Haoyu
    Long, Yanqin
    Li, Xiaoqing
    Sun, Xiaohong
    Lan, Yu
    Gao, Lingling
    Zhang, Lu
    Feng, Zenghui
    Hou, Xiaohua
    TRIALS, 2020, 21 (01)